IPP Bureau
Biocon Biologics' Drug Substance Facility in Bengaluru cassified as VAI
By IPP Bureau - November 29, 2025
This relates to the manufacture and supply of Human Recombinant Insulin (rh- Insulin) and Biosimilar Pegfilgrastim Drug Substance to the United States
Mangalam Drugs receives Rs. 15 crore repeat export order
By IPP Bureau - November 29, 2025
The receipt of this order further strengthens the company's position in the global pharmaceutical market
.jpg "Cipla opens India's First dedicated lung health diagnostics center in Delhi")
Cipla opens India's First dedicated lung health diagnostics center in Delhi
By IPP Bureau - November 29, 2025
Amrutanjan re-launches its iconic yellow balm
By IPP Bureau - November 29, 2025
Amrutanjan is also rolling out its new campaign, 'Har Dard Mitaye'
Innoxel Lifesciences completes EU GMP inspection by Belgium's FAMHP
By IPP Bureau - November 29, 2025
The audit was completed with zero critical and zero major observations
Lupin Foundation bags CRISIL's Highest VO 1A rating for Excellence in Social Responsibility
By IPP Bureau - November 29, 2025
This distinction is testament to LHWRF's dedication to excellence, transparency, and impact in the realm of social responsibility
Akums Drugs appoints Yuvraj Datta as President – Operational Strategy & Excellence
By IPP Bureau - November 28, 2025
Most recently, Yuvraj was the Director of Operations, Business Development & Process Excellence at Zeon Lifesciences Ltd
Apollo Pharmacy becomes 7,000-store strong
By IPP Bureau - November 28, 2025
The 7,000th store was inaugurated in Ayodhya, Uttar Pradesh
Medanta launches 550-bed super speciality hospital in Noida
By IPP Bureau - November 28, 2025
The hospital has already onboarded 200+ experienced doctors and is expected to generate 5,000–7,000 jobs
Piramal Pharma Solutions achieves global nitrosamine compliance, strengthening patient safety
By IPP Bureau - November 28, 2025
Nitrosamines have prompted evolving global guidelines that demand rigorous industry oversight
Renalys Pharma reports major phase III success for Sparsentan in Japanese IgA nephropathy patients
By IPP Bureau - November 28, 2025
The study, which enrolled 35 Japanese patients, evaluated the percent change from baseline in the 24-hour urine protein-to-creatinine ratio
Exyte completes Pharmaplan integration
By IPP Bureau - November 28, 2025
Pharmaplan brings a pan-European footprint of locations and specialist teams, now operating within Exyte’s Biopharma & Life Sciences division
GV20 Therapeutics hits milestone in AI-driven cancer therapy collaboration with Mitsubishi Tanabe Pharma
By IPP Bureau - November 28, 2025
GV20 received an upfront payment and is eligible for additional milestone payments
Ovation.io and PrecisionLife team to develop drug-response biomarkers for GLP-1 therapies
By IPP Bureau - November 28, 2025
GLP-1 therapies are among the fastest-growing drug classes worldwide, projected to drive a $95 billion obesity market by 2030
Transmural Systems wins breakthrough FDA nod for coronary-saving TAVR device
By IPP Bureau - November 27, 2025
The clearance for TELLTALE positions Transmural Systems at the forefront of next-generation electrosurgical solutions for structural heart interventions
